A Phase 1 interventional study of DWP16001 0.3mg and DWC202407 1,000mg in Healthy, sponsored by Daewoong Pharmaceutical Co. LTD.. Not yet recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-16.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to evaluate the pharmacokinetic/pharmacodynamic drug-drug interactions between DWP16001, DWC202407, and DWC202408 in healthy adults
This study aims to evaluate the pharmacokinetic interactions, pharmacodynamic interactions, safety, and tolerability of DWP16001, DWC202407, and DWC202408 in healthy adults
Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: DWP16001 0.3mg
Drug: DWC202407 1,000mg
Drug: DWC202408 2mg
1 tablet, Orally, Once daily single dose
1 tablet, Orally, Twice daily
1 tablet, Orally, Once daily single dose
Cmax,ss of DWP16001
Peak Plasma Concentration at steady-state
Time frame: 0-24 hours
AUCtau,ss of DWP16001
Area under the plasma concentration versus time curve at Tau, steady-state
Time frame: 0-24 hours
Cmax,ss of DWC202407
Peak Plasma Concentration at steady-state
Time frame: 0-12 hours
AUCtau,ss of DWC202407
Area under the plasma concentration versus time curve at Tau, steady-state
Time frame: 0-12 hours
Cmax,ss of DWC202408
Peak Plasma Concentration at steady-state
Time frame: 0-24 hours
AUCtau,ss of DWC202408
Area under the plasma concentration versus time curve at Tau, steady-state
Time frame: 0-24 hours
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2024; primary completion for Dec 2024, 1 month later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enavogliflozin
Daewoong Pharmaceutical Co. LTD. →